Humira denied by insurance? Appeal and win.
With biosimilars now common, Humira denials often involve a biosimilar-first requirement. A specialist letter documenting why the specific therapy is necessary is the key to approval.
Reviewed by the Apellica Appeals Team · Updated June 2026
Carrier names and logos are trademarks of their respective owners. Apellica is independent and not affiliated with any insurance carrier or carrier's appeal program.
Rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, and related conditions.
Why Humira gets denied
- Step therapy or biosimilar-first requirement
- Prior-authorization criteria not documented
- Diagnosis not evidenced
- Non-preferred versus a biosimilar
What a winning appeal includes
- Confirmed diagnosis
- Prior therapy history, including any biosimilar trials
- Specialist support
- A letter of medical necessity
How we approach the appeal
Document the diagnosis and any biosimilar trials, and explain the clinical reason the prescribed therapy is necessary.
Internal appeals: 30 days pre-service, 60 days post-service, 72 hours urgent. File within 180 days.
$0 upfront. We assess fit first, then build and file the appeal for you.
- · The denial letter and your Explanation of Benefits (EOB)
- · Insurance ID, plan name, and the claim or prior-authorization number
- · Diagnosis with ICD-10 code and the prescriber's clinical notes
- · A record of treatments already tried and how they worked
Appealing a Humira denial by insurer
The path depends on who manages your benefit. The most common:
Coverage runs through the pharmacy benefit. Appeal the coverage determination and, when the drug is non-formulary, file a formulary or tier exception with a provider attestation that covered alternatives are unsuitable.
Publishes detailed prior-authorization criteria. A denial usually means a criterion was not documented. Appeal through a coverage review, with a formulary exception for excluded drugs.
Administers many UnitedHealthcare and employer plans. Appeals and exceptions follow the plan's published PA criteria; expedited review exists for urgent cases.
Internal appeal first, then independent external review. Pre-service decisions are generally made within 30 days, urgent within 72 hours.
Internal appeals and external review; pharmacy denials often route through OptumRx criteria.
Independent state plans, so criteria vary. Match the appeal to your specific BCBS plan, internal appeal first, then external review.
Frequently asked questions
My plan wants a biosimilar first. Can I appeal?
Yes. A step-therapy override can apply when the biosimilar is unsuitable, has failed, or is contraindicated, with specialist documentation.
Humira denied? We fight it for you.
$0 upfront. Two-minute intake. We confirm fit and reply within one business day with the right path for your situation.
Start Your AppealThis page provides general information about appeal strategy. It is not legal or medical advice. Apellica is not a law firm. Outcomes depend on documentation, plan terms, and timing.